Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
115 hedge funds and large institutions have $143M invested in Provention Bio, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 32 reducing their positions, and 25 closing their positions.
58% more call options, than puts
Call options by funds: $3.51M | Put options by funds: $2.22M
25% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 32
8% less funds holding
Funds holding: 125 → 115 (-10)
27% less capital invested
Capital invested by funds: $197M → $143M (-$53.6M)
40% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sessa Capital
New York
|
+$9.05M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$4.51M |
| 3 |
DCM
DG Capital Management
New York
|
+$3.5M |
| 4 |
Millennium Management
New York
|
+$1.41M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$24.5M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$2.43M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$1.52M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.43M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$1.15M |
PRVB Hedge Fund Activity: Q3 2021 in Review
115 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q3 2021, worth a combined $143M — down 27% from $197M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of PRVB and 15 opened new positions — a net loss of 10 holders — while 32 trimmed existing stakes and 40 added.
The largest buyer was Sessa Capital, adding an estimated $9.05M. The largest seller was VR Adviser, exiting entirely with an estimated $24.5M sold.
- 115 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q3 2021, down from 125 in Q2 2021.
- Funds reported $143M of Provention Bio, Inc. Common Stock stock for Q3 2021, down 27% quarter-over-quarter.
- 15 funds opened new Provention Bio, Inc. Common Stock positions in Q3 2021 and 25 closed out, a net change of -10 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q3 2021 was Sessa Capital, an estimated $9.05M added.
- The largest Provention Bio, Inc. Common Stock seller in Q3 2021 was VR Adviser, an estimated $24.5M sold.
Based on aggregated 13F filings for Q3 2021.